全文获取类型
收费全文 | 4707篇 |
免费 | 292篇 |
国内免费 | 115篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 76篇 |
妇产科学 | 99篇 |
基础医学 | 301篇 |
口腔科学 | 10篇 |
临床医学 | 741篇 |
内科学 | 893篇 |
皮肤病学 | 53篇 |
神经病学 | 362篇 |
特种医学 | 63篇 |
外科学 | 481篇 |
综合类 | 866篇 |
预防医学 | 133篇 |
眼科学 | 46篇 |
药学 | 804篇 |
4篇 | |
中国医学 | 98篇 |
肿瘤学 | 80篇 |
出版年
2024年 | 6篇 |
2023年 | 42篇 |
2022年 | 51篇 |
2021年 | 124篇 |
2020年 | 113篇 |
2019年 | 112篇 |
2018年 | 124篇 |
2017年 | 120篇 |
2016年 | 128篇 |
2015年 | 175篇 |
2014年 | 342篇 |
2013年 | 401篇 |
2012年 | 290篇 |
2011年 | 299篇 |
2010年 | 232篇 |
2009年 | 199篇 |
2008年 | 222篇 |
2007年 | 227篇 |
2006年 | 198篇 |
2005年 | 174篇 |
2004年 | 180篇 |
2003年 | 159篇 |
2002年 | 148篇 |
2001年 | 144篇 |
2000年 | 102篇 |
1999年 | 85篇 |
1998年 | 70篇 |
1997年 | 74篇 |
1996年 | 64篇 |
1995年 | 45篇 |
1994年 | 64篇 |
1993年 | 31篇 |
1992年 | 25篇 |
1991年 | 39篇 |
1990年 | 29篇 |
1989年 | 22篇 |
1988年 | 22篇 |
1987年 | 20篇 |
1986年 | 21篇 |
1985年 | 30篇 |
1984年 | 30篇 |
1983年 | 30篇 |
1982年 | 31篇 |
1981年 | 9篇 |
1980年 | 21篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1977年 | 9篇 |
1976年 | 10篇 |
1975年 | 4篇 |
排序方式: 共有5114条查询结果,搜索用时 281 毫秒
31.
Caenazzo C.; Garbisa S.; Ceol M.; Baggio B.; Borsatti A.; Marchi E.; Gambaro G. 《Nephrology, dialysis, transplantation》1995,10(2):175-184
Glycosaminoglycan administration has favourable effects on morphologicaland functional renal abnormalities in different models. Thepossibility that exogenous glycosaminoglycans modulate glomerularmatrix synthesis was explored in both primary and SV40-MES13murine mesangial cell cultures. On both cell types, both low-molecular-weightheparin and different glycosaminoglycans showed dose-dependentinhibition of proliferation and increase of 35SO24 uptake.After 36 h the cell compartment contained a spectrum of 35S-moleculesof less than 200 kDa; under heparin treatment, the two main35SO24 components (high and medium MW) increased by 16and 37% respectively. Susceptibility to glycosidases revealedthat heparin promotes the expression of heparan sulphate andincreases that of chondroitin sulphate. Moreover, heparin modifiesthe expression of decorin and bigly-can, involved in adhesionand fibrillogenesis, while not affecting perlecan. The extracellularmatrix modulation in renal cells, for which the sulphation typeand ratio of heparin are crucial, may thus explain the beneficialrenal effects of heparin. 相似文献
32.
肝素涂层体外循环管道抗凝血性能的研究 总被引:2,自引:1,他引:2
目的 评测3种离子键肝素涂层体外循环管道的抗凝血性能和稳定性。方法 用PT和APTT对不同浓度肝素—氯烃基二甲基代苯甲胺(HBC)复合物涂层体外循环管道的凝血性能进行评测,同时测试体外转流对3种肝素涂层管道抗凝血性能的影响。结果 3种肝素涂层方法均能够将肝素分子结合于材料表面并具有抗凝活性,其中HBC复合物和肝素—聚乙烯亚胺复合物处理的体外循环管道经体外转流96h后仍具有较佳的抗凝血活性。结论 离子键肝素涂层因结合物质不同其稳定性也不同;HBC复合物和肝素—聚乙烯亚胺复合物处理的体外循环管道肝素分子结合较牢固,能够满足临床短期使用需要。 相似文献
33.
A. K. Chepurov Z. M. Belomestnaya I. A. Donetskii G. V. Tsidvintseva 《Bulletin of experimental biology and medicine》1980,89(3):289-292
The thromboresistant properties of hydrophilic gels based on copolymers of nitrogen-containing heterocyclic vinyl compounds with vinyl monomers were investigated. The hydrophilic gels were shown to prevent adsorption of fibrinogen, activation of procoagulants, and adhesion of platelets. Hydrogen surfaces possess selective affinity for plasma albumin. The authors consider that the thromboresistant effect of hydrophilic gels is due to the competitive action of plasma albumin. Modification of hydrophilic gels increases their thromboresistant properties.Laboratory of Thromboresistant Materials, Institute of Transplantation of Organs and Tissues, Ministry of Health of the USSR, Moscow. (Presented by Academician of the Academy of Medical Sciences of the USSR A. M. Chernukh.) Translated from Byulleten' Éksperimental'noi Biologii i Meditsiny, Vol. 89, No. 3, pp. 296–298, March, 1980. 相似文献
34.
35.
G. Patriarca M. Rossi D. Schiavino G. Schinco G. Fais C. Varano R. Schiavello 《Allergy》1994,49(4):292-294
Among all the known drug intolerances, adverse reactions to heparin are not very common. No desensitization in patients with heparin hypersensitivity has ever been attempted. We report the case of a 55–year-old female patient with mitral stenosis and insufficiency, and tricuspid and aortic insufficiency. The patient underwent heparin treatment, and urticaria occurred with either s.c. calcium heparin or i.v. sodium heparin. Allergy testing (skin tests and patch tests) was negative. A pseudoallergic intolerance was diagnosed. Mitral valve replacement with the extracorporeal circulation method was necessary; therefore, heparin treatment was administered. A heparin rush desensitization together with antihistamine drugs (4 mg clorpheniramine maleate for 3 d) was started: 50 UI (0.5 mg) s.c. sodium heparin were first administered; within 4 d, 5000 UI (50 mg) sodium heparin was administered i.v. with no side-effects. A full-dosage heparin treatment was then administered and heart surgery was easily performed. During the postsurgical course, i.v. sodium heparin was smoothly replaced with s.c. calcium heparin (25000 UI s.c. per day) and with oral anticoagulants (sodium warfarin). 相似文献
36.
37.
Anticoagulant Activity of Fucoidan from Brown Algae Fucus evanescens of the Okhotsk Sea 总被引:2,自引:0,他引:2
Kuznetsova TA Besednova NN Mamaev AN Momot AP Shevchenko NM Zvyagintseva TN 《Bulletin of experimental biology and medicine》2003,136(5):471-473
In vitro and in vivo experiments showed that anticoagulant activity of sulfated polysaccharide from Fucus evanescens (brown algae of the Okhotsk Sea) was similar to that of heparin. Anticoagulant properties of fucoidan are determined by thrombin inhibition mediated via plasma antithrombin III. 相似文献
38.
39.
Soulika AM Khan MM Hattori T Bowen FW Richardson BA Hack CE Sahu A Edmunds LH Lambris JD 《Clinical immunology (Orlando, Fla.)》2000,96(3):212-221
Complement activation products are major components of the inflammatory response induced by cardiac surgery and cardiopulmonary bypass which contribute to postoperative organ dysfunction, fluid accumulation, and morbidity. Activation of the complement system occurs during extracorporeal circulation, during reperfusion of ischemic tissue, and after the formation of heparin-protamine complexes. In this study we examine the efficacy of Compstatin, a recently discovered peptide inhibitor of complement, in preventing heparin/protamine-induced complement activation in baboons. The study was performed in baboons because Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans); Compstatin inhibits only the activation of primates' complement system. After testing various doses and administration regimens, Compstatin produced complete inhibition at a total dose of 21 mg/kg when given as a combination of bolus injection and infusion. Compstatin completely inhibited in vivo heparin/protamine-induced complement activation without adverse effects on heart rate or systemic arterial, central venous, and pulmonary arterial pressures. This study indicates that Compstatin is a safe and effective complement inhibitor that has the potential to prevent complement activation during and after clinical cardiac surgery. Furthermore, Compstatin can serve as the prototype for designing an orally administrated drug. 相似文献
40.
Summary The purpose of our study was to check whether the dosage recommended for the low molecular weight heparin tested here, i.e., 50% of the corresponding unfractionated heparin dose, is adequate to prevent clot formation in the extracorporeal system. Sixteen dialysis treatments of 4–5 h were given to each of six chronic dialysis patients. In dialyses 1, 2, 15 and 16 unfractionated heparin (initial dose 35 IU/kg, continuous dose 20 IU/kg/h) was given, and in dialyses 3–14 low molecular weight heparin (initial dose 17.5 anti-Xa U/kg, continuous dose 10 anti-X U/kg/h). At these dose levels of low molecular weight heparin, clot formation occurred in the extracorporeal system in five of the six patients, despite the fact that the plasma anti-Xa level of 0.5 U/ml recommended by the manufacturer had been attained. For this reason the continuous dose of low molecular weight heparin had to be raised to approx. 80% of the corresponding continuous dose of unfractionated heparin. A plasma anti-Xa level of 0.7 U/ml is necessary to prevent extracorporeal clot formation.Abbreviations anti-Xa U
Anti-factor Xa unit
- aPTT
Activated partial thromboplastin time
- AT III
Antithrombin III
- IU
International unit
- LMWH
Low molecular weight heparin
- UFH
Unfractionated heparin 相似文献